Emerging Therapies for Relapsed or Refractory Mantle Cell Lymphoma

Michael Wang, MD


February 09, 2022

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma. Although most patients respond well to treatment, some can be refractory to first-line therapy or relapse at some point.

In this ReCAP, Dr Michael Wang from MD Anderson Cancer Center discusses how new and emerging treatment options are being used to prolong survival in patients with relapsed or refractory MCL.

Dr Wang explains how targeted therapy has enabled patients to be treated without the toxicities of traditional chemotherapy. In particular, Bruton tyrosine kinase (BTK) inhibitors have become a critical means of targeting B cells and killing the lymphoma.

In addition to BTK inhibitors, Dr Wang examines the role of immunotherapy, including immunomodulatory agents such as polatuzumab, which is already approved for large cell lymphoma, and mosunetuzumab, a CD20 antibody that is being studied in MCL. He also reports on zilovertamab vedotin, a novel ROR1-targeted antibody-drug conjugate that is being studied in clinical trials.

Dr Wang also outlines how CAR T-cell therapies targeting CD19 are being used to kill lymphoma cells in MCL while other targets continue to be studied.

He concludes by outlining why the treatment approach in relapsed or refractory MCL relies on multidrug regimens to improve survival.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.